bluebird bio (NASDAQ:BLUE) Earns Hold Rating from Stifel Nicolaus

Stifel Nicolaus reiterated their hold rating on shares of bluebird bio (NASDAQ:BLUE) in a research note released on Wednesday, TipRanks reports.

Other research analysts also recently issued research reports about the company. BidaskClub upgraded bluebird bio from a strong sell rating to a sell rating in a report on Tuesday, September 17th. Maxim Group upgraded bluebird bio from a hold rating to a buy rating and set a $160.00 price target on the stock in a report on Tuesday, June 18th. BMO Capital Markets lowered their price target on bluebird bio from $191.00 to $163.00 and set an outperform rating on the stock in a report on Monday, June 17th. Piper Jaffray Companies set a $120.00 price target on bluebird bio and gave the company a hold rating in a report on Friday, June 14th. Finally, Gabelli restated a buy rating on shares of bluebird bio in a research note on Friday, July 19th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of Buy and an average price target of $149.31.

Shares of BLUE stock opened at $88.14 on Wednesday. bluebird bio has a 1-year low of $84.01 and a 1-year high of $163.43. The company has a current ratio of 8.02, a quick ratio of 8.02 and a debt-to-equity ratio of 0.11. The stock’s fifty day simple moving average is $99.41 and its 200-day simple moving average is $124.53.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($3.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.04) by ($0.51). bluebird bio had a negative net margin of 1,158.04% and a negative return on equity of 35.90%. The business had revenue of $13.30 million for the quarter, compared to analysts’ expectations of $13.13 million. During the same quarter in the prior year, the firm posted ($2.91) EPS. The business’s quarterly revenue was up 68.4% compared to the same quarter last year. Equities analysts predict that bluebird bio will post -13.35 earnings per share for the current year.

In other bluebird bio news, insider David Davidson sold 2,060 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $100.16, for a total value of $206,329.60. Following the transaction, the insider now owns 34,616 shares in the company, valued at $3,467,138.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Philip D. Gregory sold 950 shares of the business’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $124.03, for a total value of $117,828.50. Following the completion of the transaction, the insider now owns 31,042 shares in the company, valued at approximately $3,850,139.26. The disclosure for this sale can be found here. Insiders sold 5,460 shares of company stock worth $593,836 in the last 90 days. Corporate insiders own 3.00% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Trust Co. of Vermont boosted its stake in shares of bluebird bio by 40.6% during the 2nd quarter. Trust Co. of Vermont now owns 253 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 73 shares in the last quarter. LPL Financial LLC boosted its stake in shares of bluebird bio by 1.6% during the 2nd quarter. LPL Financial LLC now owns 5,373 shares of the biotechnology company’s stock worth $683,000 after acquiring an additional 84 shares in the last quarter. Capital Investment Advisory Services LLC boosted its stake in shares of bluebird bio by 100.0% during the 2nd quarter. Capital Investment Advisory Services LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 100 shares in the last quarter. First Light Asset Management LLC boosted its stake in shares of bluebird bio by 0.5% during the 2nd quarter. First Light Asset Management LLC now owns 18,840 shares of the biotechnology company’s stock worth $2,396,000 after acquiring an additional 103 shares in the last quarter. Finally, Clearbridge Investments LLC boosted its stake in shares of bluebird bio by 18.2% during the 1st quarter. Clearbridge Investments LLC now owns 839 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 129 shares in the last quarter.

bluebird bio Company Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

Further Reading: What are benefits of a growth and income fund?

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.